Gimv Life Sciences realizes successful exit with the sale of its stake in Imcheck Therapeutics to Ipsen

Gimv announces the sale of its stake in ImCheck Therapeutics to Ipsen, marking a significant milestone for both companies. This transaction highlights Gimv’s strategic approach to valorizing investments in the life sciences sector, demonstrating how our support for scientific innovation not only creates tangible value for shareholders, but also benefits society at large by advancing the medical field through the introduction of new treatments.

ImCheck Therapeutics, a French biotechnology company, has developed a next-generation antibody pipeline with its lead program, ICT01, showing highly encouraging results in acute myeloid leukemia (AML). The Phase I/II EVICTION trial has demonstrated nearly double the treatment response compared to historical standards, positioning ICT01 as a potential new standard of care for high-risk, unfit AML patients.

Ipsen’s acquisition of all issued and outstanding shares of ImCheck Therapeutics, for a closing purchase price of 350 million euro and potential milestone payments totaling nearly 1 billion euro, reflects the significant value created by ImCheck’s team, scientific founders, and investors. This transaction validates the impact of collaborative investment in transformative healthcare solutions.

Rishabh Chawla, Principal in Gimv’s Life Sciences team declares: “Gimv is proud to have supported ImCheck’s journey from academic research to late-stage clinical development. The sale to Ipsen not only delivers substantial returns to our stakeholders but also ensures that ImCheck’s innovative therapies will reach patients worldwide, backed by Ipsen’s global development and commercialization expertise.”

Bram Vanparys, Managing Partner and board member at Imcheck Therapeutics, adds: “This exit highlights Gimv’s strategy of investing in high-potential life sciences companies and partnering with visionary teams to advance medical breakthroughs. We congratulate ImCheck Therapeutics and Ipsen on this landmark transaction and look forward to seeing ICT01 and future pipeline assets make a lasting impact in oncology and beyond.”

As a result of this transaction, Gimv will receive an upfront cash payment that represents a realized money multiple of 2.6x on our total investment and a positive impact of approximately 0.4 euro per share compared to the unaudited NAV communicated in the trading update at the beginning of September. Should all regulatory and sales-based milestones be achieved, this could result in a potential total money multiple of 7.1x, subject to the successful completion of these milestones.

The transaction is expected to close by the end of Q1 2026, subject to fulfilment of customary closing conditions including the expiration or termination of any required regulatory and governmental approvals under French and U.S. regulations.